Company
Every investor coverage indicates participated in a round NeuroScientific Biopharmaceuticals raised.
Companies NeuroScientific Biopharmaceuticals acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Nathan Smith | Chief Executive | Biotech Dispatch |
Stories naming NeuroScientific Biopharmaceuticals. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Regulators have favourably answered most of the biotech's questions ahead of a planned mid-stage stem cell therapy trial, with one manufacturing concern still to resolve before the study can start.